Meditopes and meditope-binding antibodies and uses thereof
Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
1. An isolated meditope-enabled antibody or fragment thereof, comprising: a heavy chain variable (VH) region, a heavy chain constant region (CH) or portion thereof, a light chain variable (VL) region comprising a threonine, serine, or aspartate at position 40, a residue other than glycine at position 41, a residue other than phenylalanine at position 83, and an aspartate or asparagine at position 85, according to Kabat numbering, and a light chain constant region (CL) or portion thereof, wherein
the meditope-enabled antibody is a meditope-enabled variant of a human or humanized template antibody, which variant contains a plurality of framework region (FR) modifications, according to Kabat numbering, compared to the template antibody, said FR modifications being only at positions selected from the group consisting of positions 8, 9, 10, 38, 39, 40, 41, 42, 43, 44, 45, 82, 83, 84, 85, 86, 87, 99, 100, 101, 102, 103, 104, and 105 of the light chain of said template antibody, according to Kabat numbering, and positions 6, 9, 38, 39, 40, 41, 42, 43, 44, 45, 84, 86, 87, 88, 89, 90, 91, 103, 104, 105, 106, 107, 108, 109, and 110 of the heavy chain of said template antibody, according to Kabat numbering; and
the meditope-enabled antibody or fragment binds to a meditope comprising a peptide of SEQ TD NO: 1, via a meditope binding site.
2. The meditope-enabled antibody or fragment of claim 1 , wherein the VH region comprises a serine or proline at position 40 and an isoleucine at position 89, according to Kabat numbering.
3. The meditope-enabled antibody or fragment of claim 1 , wherein the VL region further comprises an isoleucine or leucine at position 10, according to Kabat numbering, and the residue at position 83 is an isoleucine.
4. The meditope-enabled antibody or fragment of claim 1 , wherein the VL region further comprises a valine or isoleucine at position 9 and a residue other than glutamine at position 100, according to Kabat numbering.
5. The meditope-enabled antibody or fragment of claim 1 , wherein the VL region has a threonine at position 40, an asparagine at position 41, and an aspartate at position 85, according to Kabat numbering.
6. The meditope-enabled antibody or fragment of claim 1 , wherein the VH region has a serine at position 40 and an isoleucine at position 89, according to Kabat numbering.
7. The meditope-enabled antibody or fragment of claim wherein the peptide is a cyclic peptide.
8. The meditope-enabled antibody or fragment of claim 1 , wherein the meditope binds to the antibody or fragment with a dissociation constant of less than 10 μM, as measured by surface plasmon resonance (SPR).
9. The meditope-enabled antibody or fragment of claim 1 , wherein the meditope binds to residues 40, 41, 83, and 85 of the VL region of the meditope-enabled antibody or fragment, according to Kabat numbering, and residues 39, 89, 10.5, and 108 of the VH region of the meditope-enabled antibody or fragment, according to Kabat numbering.
10. The meditope-enabled antibody or fragment of claim 1 , comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO:9 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:6.
11. The meditope-enabled antibody or fragment of claim 1 , wherein the FR modifications are at positions selected from the group consisting of positions 9, 10, 39, 40, 41, 42, 43, 83, and 85 of the light chain of said template antibody, according to Kabat numbering, and positions 40, 89, and 105 of the heavy chain of said template antibody, according to Kabat numbering.
12. An isolated meditope-enabled antibody or fragment thereof, comprising: a heavy chain variable (VH) region, a heavy chain constant region (CH) or portion thereof, a light chain variable (VL) region comprising a threonine or serine at position 40, an asparagine at position 41, a residue other than phenylalanine at position 83, and an aspartate or asparagine at position 85, and a light chain constant region (CL) or portion thereof, wherein:
the meditope-enabled antibody is a meditope-enabled variant of a human or humanized template antibody, which variant contains a plurality of framework region (FR) modifications, according to Kabat numbering, compared to the template antibody, said FR modifications being only at positions selected from the group consisting of positions 8, 9, 10, 38, 39, 40, 41, 42, 43, 44, 45, 82, 83, 84, 85, 86, 87, 99, 100, 101, 102, 103, 104, and 105 of the light chain of said template antibody, according to Kabat numbering, and positions 6, 9, 38, 39, 40, 41, 42, 43, 44, 45, 84, 86, 87, 88, 89, 90, 91, 103, 104, 105, 106, 107, 108, 109, and 110 of the heavy chain of said template antibody, according to Kabat numbering; and
the antibody or fragment binds to a meditope comprising a peptide of SEQ ID NO: 1 via a meditope binding site and does not specifically bind to the epitope of EGFR that is specifically bound by cetuximab.
13. The isolated meditope-enabled antibody or fragment of claim 1 , wherein the VL region comprises the amino acid sequence of SEQ ID NO: 73.
14. The isolated meditope-enabled antibody or fragment of claim 1 , wherein the VH region comprises the amino acid sequence of SEQ ID NO: 74.
15. The isolated meditope-enabled antibody or fragment of claim 1 , wherein the VL region comprises the amino acid sequence of SEQ ID NO: 75.
16. The isolated meditope-enabled antibody or fragment of claim 1 , wherein:
The VL region has a light chain framework (FR-L)1, an FR-L2, an FR-L3, and an FR-L4 of the light chain sequence set forth as SEQ ID NO: 9; and
the VH region has a heavy chain framework (FR-H) 1, an FR-H2, an FR-H3, and an FR-H4 of the heavy chain sequence set forth as SEQ ID NO: 6.
17. An isolated meditope-enabled antibody or fragment thereof, comprising: a heavy chain variable (VH) region, a heavy chain constant region (CH) or portion thereof, a light chain variable (VL) region comprising a valine or isoleucine at position 9, a threonine, serine, or aspartate at position 40, a residue other than glycine at position 41, a residue other than phenylalanine at position 83, and an aspartate or asparagine at position 85, according to Kabat numbering, and a light chain constant region (CL) or portion thereof, wherein:
the meditope-enabled antibody is a meditope-enabled variant of a template antibody, wherein the template antibody is a human or humanized antibody and the meditope-enabled antibody contains a plurality of framework region (FR) modifications, according to Kabat numbering, compared to the template antibody, said FR modifications being only at positions selected from the group consisting of positions 8, 9, 10, 38, 39, 40, 41, 42, 43, 44, 45, 82, 83, 84, 85, 86, 87, 99, 100, 101, 102, 103, 104, and 105 of the light chain of said template antibody, according to Kabat numbering, and positions 6, 9, 38, 39, 40, 41, 42, 43, 44, 45, 84, 86, 87, 88, 89, 90, 91, 103, 104, 105, 106, 107, 108, 109, and 110 of the heavy chain of said template antibody according to Kabat numbering; and
the meditope-enabled antibody or fragment binds to a meditope comprising a peptide of SEQ ID NO: 1, via a meditope binding site and does not specifically bind to the epitope of EGFR that is specifically bound by cetuximab.
18. The meditope-enabled antibody or fragment thereof of claim 1 , wherein:
the meditope-enabled antibody or fragment competes for antigen binding with, binds to the same epitope as an antibody or antigen-binding fragment thereof selected from the group consisting of abagovomab, abciximab, adalimumab, adecatumumab, alemtuzumab, altumomab, altumomab pentetate, anatumomab, anatumomab mafenatox, arcitumomab, atlizumab, basiliximab, bectumomab, ectumomab, belimumab, benralizumab, bevacizumab, brentuximab, canakinumab, capromab, capromab pendetide, catumaxomab, certolizumab, clivatuzumab tetraxetan, daclizumab, denosumab, eculizumab, edrecolomab, efalizumab, etaracizumab, ertumaxomab, fanolesomab, fontolizumab, gemtuzumab, girentuximab, golimumab, ibritumomab, igovomab, infliximab, ipilimumab, labetuzumab, mepolizumab, muromonab, muromonab-CD3, natalizumab, necitumumab nimotuzumab, ofatumumab, omalizumab, oregovomab, palivizumab, panitumumab, ranibizumab, rituximab, satumomab, sulesomab, ibritumomab, ibritumomab tiuxetan, tocilizumab, tositumomab, trastuzumab, ustekinumab, visilizumab, votumumab, zalutumumab, brodalumab, anrukinzumab, bapineuzumab, dalotuzumab, demcizumab, ganitumab, inotuzumab, mavrilimumab, moxetumomab pasudotox, rilotumumab, sifalimumab, tanezumab, tralokinumab, tremelimumab, and urelumab; or
the meditope-enabled antibody or fragment specifically binds to an antigen selected from the group consisting of: CA-125, glycoprotein (GP) IIb/IIIa receptor, TNF-alpha, CD52, TAG-72, Carcinoembryonic antigen (CEA), interleukin-6 receptor (IL-6R), IL-2, interleukin-2 receptor a-chain (CD25), CD22, B-cell activating factor, interleukin-5 receptor (CD125), VEGF, VEGF-A, CD30, IL-1beta, prostate specific membrane antigen (PSMA), CD3, EpCAM, EGF receptor (EGFR), MUC1, human interleukin-2 receptor, Tac, RANK ligand, C5R, or other complement proteins, CD11a, alpha-v beta-3 integrin, HER2, neu, CD15, CD20, Interferon gamma, CD33, CA-TX, CTLA-4, TL-5, CD3 epsilon, CAM, Alpha-4-integrin, IgE, IgE Fc region, an RSV antigen, F (or fusion) protein of respiratory syncytial virus (RSV), NCA-90 (granulocyte cell antigen), TL-6, GD2, GD3, IL-12, IL-23, IL-17, CTAA16.88, beta-amyloid, IGF-1 receptor (IGF-1R), delta-like ligand 4 (DLL4), alpha subunit of granulocyte macrophage colony stimulating factor receptor, hepatocyte growth factor, IFN-alpha, nerve growth factor, IL-13, CD326, PD-L1, CD47, and CD137.
19. An isolated meditope-enabled antibody or fragment thereof, comprising: a heavy chain variable (VH) region, a heavy chain constant region (CH) or portion thereof, a light chain variable (VL) region comprising an isoleucine or leucine at position 10, a threonine, serine, or aspartate at position 40, a residue other than glycine at position 41, an isoleucine at position 83, and an aspartate or asparagine at position 85, according to Kabat numbering, and a light chain constant region (CL) or portion thereof, wherein:
the meditope-enabled antibody is a meditope-enabled variant of a template antibody, wherein the template is a human or humanized antibody and the meditope-enabled antibody contains a plurality of framework region (FR) modifications, according to Kabat numbering, compared to the template antibody, said FR modifications being only at positions selected from the group consisting of positions 8, 9, 10, 38, 39, 40, 41, 42, 43, 44, 45, 82, 83, 84, 85, 86, 87, 99, 100, 101, 102, 103, 104, and 105 of the light chain of said template antibody, according to Kabat numbering, and positions 6, 9, 38, 39, 40, 41, 42, 43, 44, 45, 84, 86, 87, 88, 89, 90, 91, 103, 104, 105, 106, 107, 108, 109, and 110 of the heavy chain of said template antibody, according to Kabat numbering; and
the meditope-enabled antibody or fragment binds to a peptide meditope comprising SEQ TD NO: 1 via a meditope binding site and does not specifically bind to the epitope of EGFR that is specifically bound by cetuximab.
20. The isolated meditope-enabled antibody of claim 1 , wherein the VL region comprises an isoleucine or leucine at position 10, a threonine at position 40, an asparagine at position 41; an isoleucine at position 83, and an aspartate at position 85, according to Kabat numbering; and the VH region comprises an isoleucine at position 89, according to Kabat numbering.
21. The isolated meditope-enabled antibody of claim 1 , wherein the VL region comprises an isoleucine or valine at position 9, an isoleucine or leucine at position 10, an arginine at position 39, a threonine at position 40, an asparagine at position 41, a glycine at position 42, a serine at position 43, an isoleucine at position 83, an aspartate at position 85, and an alanine at position 100; according to Kabat numbering; and the VH region comprises a serine at position 40 and an isoleucine at position 89, according to Kabat numbering.
22. The meditope-enabled antibody or fragment thereof of claim 1 , wherein the VH region comprises an isoleucine, tyrosine, methionine, phenylalanine, or tryptophan at position 89, according to Kabat numbering.